Vanguard Capital Management
ACRV icon

Vanguard Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Vanguard Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
952,008
+229,973
+32% +$391K ﹤0.01% 3473
2026
Q1 		$1M Buy
+722,035
New +$1.26M ﹤0.01% 3550

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Capital Management's ACRV Position: Q2 2026 in Review

Vanguard Capital Management increased its Acrivon Therapeutics (ACRV) stake by 32% in Q2 2026, buying an estimated $391K and bringing the position to 952,008 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3473.

Vanguard Capital Management first reported a position in ACRV in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Vanguard Capital Management held 952,008 shares of Acrivon Therapeutics worth $1.69M as of Q2 2026.
  • Vanguard Capital Management bought 229,973 Acrivon Therapeutics shares in Q2 2026, an estimated $391K.
  • Acrivon Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3473 holding.
  • Vanguard Capital Management first reported a position in Acrivon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.